If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

 

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLPE.L Regulatory News (SLPE)

  • There is currently no data for SLPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Quarterly Trading Statement

24 Mar 2016 14:00

RNS Number : 2386T
Standard Life Euro Pri Eqty Tst PLC
24 March 2016
 

Standard Life European Private Equity Trust PLC

 

1. Investment update for the quarter from 1 October to 31 December 2015

 

· NAV increased 3.5% to 291.5p for the quarter ended 31 December 2015

· Realised gains and income were £24.0 million (6.5% of opening portfolio valuation). The unrealised losses on the portfolio on a constant exchange rate basis were £11.1 million (3.0% of opening portfolio valuation); in addition, there were unrealised foreign exchange gains on the portfolio of £1.1 million (0.3% of opening portfolio valuation)

· 100.0% by value of the portfolio was valued by the respective underlying managers at 31 December 2015

· Outstanding commitments were £240.0 million at 31 December 2015

· Cash balance was £40.5 million and £39.3 million was invested in equity index tracker funds at 31 December 2015

 

For the quarter ended 31 December 2015 the Company's net asset value per ordinary share ("NAV") increased by 3.5% to 291.5p, from 281.6p at 30 September 2015. At 31 December 2015 the Company's net assets were £454.1 million (30 September 2015 - £438.7 million).

 

In light of the volatile listed financial markets and a weakening global macro-economic environment, the quarter ended 31 December 2015 saw a decrease in new investment activity in the European private equity market. The value of all new private equity transactions in the European private equity market announced during the quarter was €35.8 billion (quarter ended 30 September 2015 - €40.5 billion), of which €29.4 billion comprised buy-out transactions (quarter ended 30 September 2015 - €34.2 billion).

 

Distributions received by the Company during the quarter ended 31 December 2015 were £45.1 million (quarter ended 30 September 2015 - £34.6 million) and the Company funded £17.0 million of draw downs (quarter ended 30 September 2015 - £12.0 million). The distributions received by the Company generated net realised gains and income of £24.0 million, which was equivalent to a return of 2.1 times the acquisition cost of the realised investments.

 

The closing value of the Company's portfolio of 47 private equity fund interests was £373.9 million at 31 December 2015 (30 September 2015 - 46 fund interests and £369.0 million). Total net unrealised losses on the portfolio for the quarter were £10.0 million, of which £11.1 million were net unrealised losses on a constant exchange rate basis and £1.1 million were net unrealised foreign exchange gains. During the quarter ended 31 December 2015, sterling was flat against the euro and depreciated by 2.7% against the US dollar.

 

In line with the Company's investment strategy, the Company acquired through a secondary purchase an original commitment of $60.0 million to TowerBrook Investors III in December 2015. The purchase price for the fund interest was £19.1 million, equivalent to a discount of 6.1% to the most recent valuation at 30 September 2015, adjusted for subsequent cashflows. The Company assumed outstanding commitments of £10.8 million on acquisition. The Company does not have an existing commitment to TowerBrook Investors III, but has existing commitments of $25.0 million and $35.0 million to TowerBrook Investors II and IV respectively.

 

At 31 December 2015 the Company had a cash balance of £40.5 million and had £39.3 million invested at value (£39.2 million at cost) in UK and European equity index tracker funds. The Company has an undrawn £80 million syndicated revolving credit facility, provided by Citi and Societe Generale, that expires in December 2020.

 

At 31 December 2015 the Company had total outstanding commitments of £240.0 million to 47 private equity fund interests (30 September 2015 - £245.8 million and 46 fund interests). After undertaking a detailed review, the Manager now believes that up to £55 million of the Company's existing outstanding commitments are unlikely to be drawn (30 September 2015 - £50 million).

 

2. Events and transactions since 1 January 2016

 

During the period from 1 January to 23 March 2016 the Company received £29.2 million of distributions and funded £16.0 million of draw downs.

 

A new commitment of €45.0 million was made to Advent International GPE VIII in February 2016. At 23 March 2016 the Company had total outstanding commitments of £271.4 million.

 

On 29 January 2016 the Company paid a final dividend for the year ended 30 September 2015 of 3.5p per ordinary share (total for the year of 5.25 pence per share). The cost of the final dividend was £5.5 million.

 

At 23 March 2016 the Company had a cash balance of £50.1 million and had £39.7 million invested at value (£39.2 million at cost) in UK and European equity index tracker funds.

 

The Company's estimated NAV at 29 February 2016 is also being announced today. It is anticipated that the Company will release its interim announcement for the six months ending 31 March 2016 on 27 May 2016.

 

For further information please contact:-

 

Peter McKellar or Roger Pim at SL Capital Partners LLP (0131 245 0055)

 

Note:-

Standard Life European Private Equity Trust PLC is an investment company managed by SL Capital Partners LLP, the ordinary shares of which are admitted to listing by the UK Listing Authority and to trading on the Stock Exchange and which seeks to conduct its affairs so as to qualify as an investment trust under section 1158 of the Corporation Tax Act 2010. The Board of Standard Life European Private Equity Trust PLC is independent of Standard Life plc.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCXZLFLQXFXBBL
Date   Source Headline
4th Apr 202212:06 pmRNSChange of Name
22nd Mar 20222:14 pmRNSResult of AGM
21st Mar 202211:26 amRNSDirector Declaration
14th Mar 20225:30 pmRNSFTSE Russell Indices
14th Mar 20227:00 amRNSEstimated NAV at 28 February 2022
9th Mar 20222:07 pmRNSFirst Interim Dividend
24th Feb 20227:00 amRNSEdison review on Standard Life Private Equity Trst
14th Feb 20227:00 amRNSEstimated NAV at 31 January 2022
4th Feb 20223:24 pmRNSAnnual Report
1st Feb 202212:45 pmRNSDirector/PDMR Shareholding
27th Jan 20227:05 amRNSEstimated NAV at 31 December 2021
27th Jan 20227:00 amRNSAnnual Financial Report
6th Jan 20229:04 amRNSQuarterly disclosure
15th Dec 20217:00 amRNSEstimated NAV as at 30 November 2021
14th Dec 20213:48 pmRNSFourth Interim Dividend
6th Dec 20217:00 amRNSEdison review on Standard Life Private Equity Trst
12th Nov 20217:00 amRNSEstimated NAV at 31 October 2021
2nd Nov 20214:25 pmRNSDirector/PDMR Shareholding
14th Oct 20217:00 amRNSEstimated NAV at 30 September 2021
4th Oct 20214:15 pmRNSQuarterly disclosure
29th Sep 20217:02 amRNSEstimated NAV at 31 August 2021
29th Sep 20217:00 amRNSQuarterly Investment Update at 30 June 2021
17th Sep 20211:10 pmRNSUpdate research from QuotedData
7th Sep 20217:00 amRNSThird Interim Dividend
1st Sep 20217:00 amRNSDirectorate Change
16th Aug 202110:19 amRNSDirector/PDMR Shareholding
13th Aug 20217:00 amRNSEstimated NAV at 31 July 2021
10th Aug 20214:41 pmRNSSecond Price Monitoring Extn
10th Aug 20214:35 pmRNSPrice Monitoring Extension
5th Aug 20213:32 pmRNSDirector/PDMR Shareholding
19th Jul 202111:58 amRNSEdison issues review on Standard Life Private
14th Jul 20219:05 amRNSDirector Declaration
14th Jul 20217:00 amRNSEstimated NAV at 30 June 2021
9th Jul 20213:29 pmRNSDoc re. Half yearly report
2nd Jul 20214:35 pmRNSQuarterly disclosure
29th Jun 20217:05 amRNSEstimated NAV at 31 May 2021
29th Jun 20217:00 amRNSHalf-year Report
14th Jun 20212:48 pmRNSSecond Interim Dividend
17th May 20217:00 amRNSEstimated NAV at 30 April 2021
12th May 20214:06 pmRNSDirector/PDMR Shareholding
27th Apr 202112:21 pmRNSDirector/PDMR Shareholding
22nd Apr 20217:05 amRNSEstimated NAV at 31 March 2021
22nd Apr 20217:00 amRNSQuarterly Investment Update at 31 December 2020
9th Apr 202111:58 amRNSHolding(s) in Company
6th Apr 20214:11 pmRNSQuarterly disclosure
23rd Mar 20211:50 pmRNSResult of AGM
12th Mar 20217:00 amRNSEstimated NAV as at 28 February 2021
8th Mar 20217:00 amRNSFirst Interim Dividend
25th Feb 20217:00 amRNSEdison review on Standard Life Private Eqty Trust
12th Feb 202110:22 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.